AlphaYou
Overview
8 funds hold it and 9 straight earnings beats.
Key stats
Sep 7- Open
- $67.24
- 52-wk high
- $68.64
- High
- $67.72
- 52-wk low
- $41.13
- Low
- $66.58
- Prev close
- $68.09
- Mkt cap
- $136.49B
- P/E
- 14.7x
- Volume
- 4.83M
- Fwd P/E
- 10.4x
- Beta
- 0.23
- Div yield
- 3.69%
- P/S
- 2.8x
- P/B
- 6.2x
- Profit margin
- +18.9%
- Op margin
- +34.4%
- ROE
- +46.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 28.3% above what analysts expected.
Earnings per share
$1.59 expected
Reports Oct 29, 2026, in 52 days
EPS expected
$1.59 to $1.92
Revenue expected
18 analysts
Last 30 days
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $12.22B | $12.50B | $11.49B | $12.97B |
| Cost of what it sold | $3.44B | $4.10B | $3.42B | $3.73B |
| Gross profit | $8.79B | $8.41B | $8.07B | $9.25B |
| What it spent | ||||
| Research and development | $2.53B | $2.59B | $2.65B | $2.96B |
| Sales and admin | $1.79B | $2.18B | $1.62B | $1.83B |
| Other operating costs | $831.0M | $826.0M | $437.0M | $376.0M |
| Total operating expenses | $5.15B | $5.59B | $4.70B | $5.16B |
| What was left | ||||
| Operating profit | $3.64B | $2.81B | $3.37B | $4.09B |
| Interest on debt | $480.0M | $432.0M | $411.0M | $407.0M |
| Profit before tax | $3.11B | $1.47B | $3.24B | $4.09B |
| Tax | $919.0M | $384.0M | $561.0M | $770.0M |
| Net profit | $2.20B | $1.09B | $2.68B | $3.32B |
| EBITDA | $4.61B | $2.88B | $4.25B | $4.94B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
Exclusive | Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects
BearishSep 4Nykredit A S Purchases New Shares in Bristol Myers Squibb Company $BMY
NeutralSep 4Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com
Leans bullishSep 3Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock
NeutralSep 3GSK wagers up to $1.3B on a different kind of cancer drug
NeutralSep 3Eikon Therapeutics names CP Chang as chief scientific officer
NeutralSep 3Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Leans bullishSep 3Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com
NeutralSep 3
Macro
21 macro signals shaping BMY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results